Secondary Logo

Journal Logo

Review

Diagnosis and Management of Intraamniotic Infection

Fan, Shang-Rong1,2,∗; Liu, Ping1; Yan, Shao-Mei1; Peng, Ji-Ying3; Liu, Xiao-Ping4

Editor(s): Pan, Yang

Author Information
doi: 10.1097/FM9.0000000000000052
  • Open

Abstract

Introduction

Intraamniotic infection (IAI) or chorioamnionitis is described as acute infection and inflammation involving the chorion and amnion layer of the fetal membranes, amniotic fluid, and/or placental decidua.1 New terminology proposed by an expert panel in 2015 replaced IAI or chorioamnionitis with the phrase intrauterine infection, inflammation, or both (triple I) to reflect the heterogeneity of the condition.2,3 However, the American College of Obstetricians and Gynecologists still recommends the use of IAI as the term for this disorder.1 IAI may lead to serious maternal complications such as sepsis, prolonged labor, wound infection, need for hysterectomy, postpartum endometritis, postpartum hemorrhage, adult respiratory distress syndrome, intensive care unit admission, and, in rare instances, maternal death. IAI complicates 40%–70% of preterm births and 1%–13% of term births with preterm premature rupture of membranes or spontaneous labor.4 This article focuses on the clinical diagnosis and management of IAI.

Causes and risk factors

Figure 1 shows the ascending IAI. IAI develops as a result of ascending infections from the lower genital tract, most often in the setting of ruptured membranes. The infection is polymicrobial and involves vaginal or enteric flora, including anaerobes, enteric gram-negative bacilli, and group B streptococcus. The infection is rarely due to hematogenous, transplacental spreading of maternal bacteremia (eg, Listeria monocytogenes) or an invasive diagnostic procedure such as amniocentesis.5 The risk factors include alcohol use; amnioinfusion; bacterial vaginosis; epidural anesthesia; group B streptococcus colonization; high body mass index (obesity); immunocompromised state; long labor hours; long second-stage labor hours; meconium-stained amniotic fluid; high number of cervical examinations; high number of digital vaginal examinations (especially with ruptured membranes); nulliparity; periodontal disease; prolonged membrane rupture; prolonged labor; cigarette smoking; sexually transmitted infections; invasive vaginal procedures such as fetal scalp electrodes or intrauterine pressure catheters; induction with a single-balloon catheter; and twin pregnancies with preterm labor and intact membranes.6 In patients with cervical insufficiency and IAI, administration of antibiotics is followed by resolution of the intraamniotic inflammatory process or IAI in 75% of patients and has been associated with treatment success in approximately 60% of cases.5,7–10

Figure 1
Figure 1:
Stages of ascending intraamniotic infection. Most cases of microbial invasion of the amniotic cavity are the result of ascending infection from the vagina and cervix. Stage 1 is the ascending infection corresponds to a change in the vaginal/cervical microbial flora or the presence of pathologic organisms in the cervix. Stage 2 is the microorganisms gain access to the amniotic cavity. They reside in the lower pole of the uterus between the membranes and the chorion. Stage 3 is the microorganisms proceed through the amnion into the amniotic cavity that leads to an intraamniotic infection. Stage 4 is the microorganisms may invade the fetus by different ports of entry.

Organisms

Chorioamnionitis is mainly due to ascending polymicrobial bacterial infections. The organisms frequently found within the amniotic cavity are those normally present in the lower genital tract. We have reviewed and summed up the reported organisms collected by using transabdominal amniocentesis.6,11–23Figure 2 shows the organisms isolated from the amniotic fluid or placenta culture in patients with chorioamnionitis.

Figure 2
Figure 2:
The organisms isolated from the amniotic fluid or placenta culture or polymerase chain reaction (PCR) from patients with chorioamnionitis. The most frequent microorganisms found in the amniotic cavity are Ureaplasma species, Mycoplasma hominis, bacteria such as Gardnerella vaginalis, group B streptococci, Escherichia coli, Enterococcus species, Prevotella species, Peptostreptococcus species, Listeria monocytogenes, Mycobacterium tuberculosis, and Candida species such as Candida albicans, Candida glabrata, Candida parapsilosis, and Candida tropicalis.5,20–32 Several researchers found that intraamniotic infection with Ureaplasma spp. increases the risk of chorioamnionitis and preterm labor as well as neonatal morbidities.33–35 Intraamniotic and maternal inflammatory responses are more intense in intraamniotic infections with genital mycoplasmas than in intraamniotic infections with other microorganisms in patients with preterm premature rupture of membranes (PROM).36,37

Fetal listeriosis has a high mortality rate of 25%–35%, depending on the gestational age at the time of infection. Neonatal listeriosis may present as sepsis or meningitis with severe sequelae and a high case fatality rate of 20%.38 Mylonakis et al. reviewed 160 cases of maternal listeriosis infection and found that 20% of them were placenta or amniotic fluid infections, and 43% of cases were bloodstream infections. 39

The fetal inflammatory response syndrome (FIRS)

Microbial invasion of the amniotic cavity can progress to fetal invasion. Once microorganisms gain access to the fetal mucosa, they are recognized by pattern recognition receptors such as Toll-like receptors, and ligation of such receptors can induce a localized and subsequently systemic inflammatory response, FIRS, which is defined as an elevated fetal plasma concentration of interleukin-6. The major consequences of FIRS include: (1) a short interval-to-delivery; (2) high neonatal morbidity after adjustment for gestational age at birth; (3) multiple organ function involvement that includes the hematopoietic system, immune system, thymus, heart, adrenal glands, skin, lung, brain, kidney, and gut.5,40

Complications and prognosis

The complications of IAI include maternal, fetal and neonatal complications. Maternal complications include: (1) preterm labor or birth; (2) preterm premature rupture of membranes; (3) bacteremia and sepsis; (4) dysfunctional labor resulting in cesarean section delivery; (5) blood transfusion; (6) increased cesarean delivery risk; (7) postpartum hemorrhage; (8) postpartum infection; (9) rare complications, including sepsis, septic shock, disseminated intravascular coagulation, multiple organ dysfunction syndrome, and death. Fetal and neonatal complications include: (1) asphyxia; (2) bronchopulmonary dysplasia; (3) cerebral white matter damage; (4) neurodevelopmental delay; (5) cerebral palsy; (6) neonatal early onset sepsis; (7) FIRS; (8) interventricular hemorrhage; (9) long-term neurodevelopmental delay; (10) late-onset sepsis; (11) morbidity related to preterm birth; (12) necrotizing enterocolitis; (13) peri-intraventricular hemorrhage; (14) periventricular leukomalacia; (15) pneumonia; (16) premature retinopathy; (17) septic shock; (18) perinatal death.5,41–44 Patients with midtrimester cervical insufficiency and bulging fetal membranes have adverse pregnancy outcomes, and placement of a cervical cerclage is an effective therapy in those cases. Preoperative amniocentesis is crucial to exclude IAI and plays a major role in selecting patients who are the best candidates for emergency cervical cerclage.7,18,41,45–50 Amniotic fluid sludge is a marker of IAI and histological chorioamnionitis in cervical insufficiency.51 After clinical examination to rule out uterine activity, or IAI, or both, physical examination-indicated cerclage placement in patients with singleton gestations who have cervical change of the internal os may be beneficial.52Figure 3 shows a patient with histological chorioamnionitis and cervical insufficiency.

Figure 3
Figure 3:
Amniotic fluid sludge is a marker of intra-amniotic infection and/or histological chorioamnionitis in cervical insufficiency. A The cervical length of 16.3 mm and cervical dilation by 21.8 mm. B The cervical length of 3.4 mm and cervical dilation by 19.0 mm.

Diagnosis

IAI has been documented in patients with preterm labor with intact membranes, preterm prelabor rupture of membranes, cervical insufficiency, asymptomatic short cervix, idiopathic vaginal bleeding, placenta previa, stillbirth, fetal growth restriction, pregnancy with an intrauterine device, and clinical chorioamnionitis at term.5 IAI categories include suspected IAIs, confirmed IAIs and isolated maternal fever.1 The features of IAI and isolated maternal fever are described as follows.

Suspected IAI, fever without a clear source plus any of the following: (1) baseline fetal tachycardia fetal heart rate greater than 160 beats per min for 10 minutes or longer, excluding accelerations, decelerations, and periods of marked variability; (2) maternal white blood cell count greater than 15 000 per mm3 in the absence of corticosteroids; (3) definite purulent fluid from the cervical os. Confirmed IAI: all of the above plus (1) amniocentesis-proven infection through a positive Gram stain; (2) low glucose or positive amniotic fluid culture; (3) placental pathology revealing diagnostic features of infection. Isolated maternal fever: maternal oral temperature of 39.0°C or greater on any one occasion is documented fever. If the oral temperature is between 38.0°C and 39.0°C, repeat the measurement in 30 minutes; if the repeat value remains at least 38.0°C, fever is documented.1,2

Diagnostic procedures

Presumptive diagnosis is based on clinical and laboratory findings, the presence of risk factors, and the absence of other causes of maternal fever. Diagnosis can be confirmed based on objective laboratory evidence of infection in amniotic fluid obtained by amniocentesis or cesarean section. Positive amniotic fluid culture is the gold standard for diagnosis, but it is of limited clinical use because results may not be available for up to 3 days. Other amniotic fluid tests findings include positive Gram stains, low glucose levels, and elevated white blood cell counts.17,20,53 Tests for maternal blood C-reactive protein level and leukocytosis have a low sensitivity and specificity.54 Kurakazu et al. found that the combination of maternal blood and amniotic fluid biomarkers could improve the predictive accuracy of histologic chorioamnionitis.55 The sonographic evaluation of the fetal thymus is also more sensitive than the fetal biophysical profile for the diagnosis of histologic chorioamnionitis.54Table 1 shows the maternal serum and amniotic fluid diagnostic tests for chorioamnionitis.4,20,56

Table 1
Table 1:
The diagnostic tests for chorioamnionitis.

Pathology

Standardizing gross examination and histologic sampling of the placenta is important to find placental abnormal. At least 4–5 microscopic slides including sections of the umbilical cord, membrane roll, and three sections of the placental parenchyma, are examined for routine placentas. The placentas may be selected for pathologic examination or stored in a refrigerator at 4°C for approximately 1 week to submit pathologic examination if required. Freezing distorts histologic detail and should be avoided.

Histopathologic evidence of infection or inflammation in the placenta, fetal membranes, or umbilical cord vessels (funisitis) confirms the diagnosis. The histologic grading and staging of acute chorioamnionitis are described as follows.

Grade: Grade 1 (mild-moderate), individual or small clusters of maternal neutrophils diffusely infiltrating the amnion, chorionic plate, chorion laeve, and/or subchorionic fibrin. Grade 2 (severe), three or more chorionic microabscesses (microabscess: confluent neutrophils measuring at least 10–20 cells in extent) between the chorion and decidua in the membranes and/or under the chorionic plate or a continuous band of confluent chorionic polymorphonuclear leukocytes more than 10 cells in width occupying more than half of the subchorionic fibrin or one revolution of the membrane role.

Chronic (or subacute) chorioamnionitis: more than occasional maternally derived mononuclear cells (usually macrophages) in the chorionic plate (most frequently below the amnion) in cases without exogenous pigment deposition (ie, meconium, haemosiderin). Neutrophils may be rare or abundant, but coexistent acute chorioamnionitis should be present in at least one section.

Staging:

  • (1) Maternal inflammatory response: Stage 1, early acute subchorionitis/chorionitis. Stage 2, acute chorioamnionitis. Stage 3, necrotizing chorioamnionitis.
  • (2) Fetal inflammatory response: Stage 1, umbilical phlebitis/chorionic vasculitis. Stage 2, umbilical arteritis. Stage 3, concentric periphlebitis/necrotizing funisitis.
  • (3) Specific patterns: Acute villitis/fetal capillaritis: neutrophils in the villous stroma and/or the adjacent subtrophoblastic space, that is, Gram-negative bacilli. Acute intervillositis/intervillous abscesses: neutrophils within perivillous fibrin or the intervillous space, that is, streptococci, Listeria monocytogenes, and other rare bacteria. Decidual plasma cells: unequivocal plasma cells in either the decidua basalis or capsularis. Peripheral funisitis: small punctate microabscesses with neutrophils on the outer surface of the cord, that is, Candida spp infection.5,57–58Figure 4 shows the histologic changes of acute chorioamnionitis.
Figure 4
Figure 4:
The histologic changes of intraamniotic infection. A Acute chorioamnionitis is Stage 2 maternal inflammatory response; neutrophilic migration into the amniotic connective tissue is shown (arrow). B Acute subchorionitis is Stage 1 maternal inflammatory response; neutrophils in the subchorionic fibrin in the chorionic plate. The arrow represents the intervillous space. C Acute chorionic vasculitis is a Stage 1 fetal inflammatory response. D Acute intervillositis/intervillous abscesses: neutrophils within perivillous fibrin or the intervillous space. This was a patient with infectious miscarriage caused by Listeria monocytogenes. E Umbilical phlebitis shows amniotropic migration of fetal neutrophils into the muscle layer of the umbilical vein. Umbilical phlebitis represents Stage 1 fetal inflammatory response. F Umbilical arteritis is a Stage 2 fetal inflammatory response. Figures by hematoxylin-eosin (HE) staining, magnification of 200×.

Management

The management of chorioamnionitis mainly includes antibiotic therapy and delivery. Women with previable preterm premature rupture of membranes (PPROM) should be offered realistic counseling from a multidisciplinary approach. The separation of the mother and the fetus to preserve the life of the mother should prioritize delivery methods that result in a living fetus if possible, with appropriate neonatal resuscitation available. In cases where delivery of a living fetus is not possible, priority should be given to delivery methods that result in an intact fetal corpus. IAI alone is rarely an indication for cesarean delivery.1 Mifepristone/misoprostol can be used to induce labor in the midtrimester for dilation and evacuation.59 Administration of intrapartum antibiotics is recommended whenever an IAI is suspected or confirmed.60 Antibiotics should be considered in the setting of isolated maternal fever unless a source other than IAI is identified and documented. There are no randomized trials comparing the efficacy of various antibiotic regimens. The recommended antibiotic regimens for the treatment of IAI are included in Table 2.

Table 2
Table 2:
Recommended antibiotic regimens for treatment of intraamniotic infection.

Eradication of IAI after treatment with antibiotics was confirmed in 79% of patients with preterm labor, intact membranes, and IAI who had a follow-up amniocentesis. Treatment success occurred in 84% of patients who underwent follow-up amniocentesis.64 Lee et al. found that the administration of ceftriaxone, metronidazole, and clarithromycin was associated with a more successful eradication of intraamniotic inflammation/infection and prevented secondary intraamniotic inflammation/infection more frequently than an antibiotic regimen that included ampicillin and/or cephalosporins in patients with preterm PROM.16 Pustotina et al. found that intravenous antibiotic therapy at 15–24 weeks of gestation in women with amniotic fluid “sludge” can protect from infection-related complications, and demonstrated high beneficial effects of adding antibiotics to anti-inflamatory drug (indomethacin) and/or vaginal progesterone in women with a short cervix.65 Several studies have demonstrated the safe use of gentamicin during pregnancy.66–68 Gentamicin was recommended to treat IAI by the American College of Obstetricians and Gynecologists, but rarely be used in some countries such as China for safety issue.1 For about one-third of positive Ureaplasma species or Mycoplasma hominis in amniotic fluid or placenta by culture or polymerase chain reaction from patients with chorioamnionitis, a lot of studies should be done to evaluate its influence.

Neonatal management

Communication between obstetric and neonatal teams is essential for appropriate neonatal treatment. Clinical management is different for term and late preterm neonates compared with preterm neonates with a gestational age <34 weeks. When IAI is suspected or confirmed, neonates with a gestational age <34 weeks should be given antibiotic treatment as soon as cultures are performed. The duration of neonatal antimicrobial therapy is more than 5 days. The negative blood cultures of neonates are generally not reliable when their mother received broad-spectrum antibiotics before delivery. Cord blood procalcitonin is a marker significantly associated with early-onset sepsis and adverse neonatal and infantile outcomes related to in utero inflammatory status.69–70

Prevention

Expectant management of PPROM is a major cause of clinical chorioamnionitis. The main preventative strategy is the administration of antibiotics to women with PPROM, which reduces the incidence of clinical chorioamnionitis, prolongs the time to delivery, and improves neonatal outcomes.59 Some other prevention methods include treatment of periodontal disease, treatment of genitourinary tract infection, and group B streptococcus intrapartum chemoprophylaxis and minimizing invasive vaginal procedures such as the use of intrauterine pressure catheters, electronic fetal scalp electrodes, and intracervical foley bulbs.4,71

Acknowledgment

Figure 1 was drawn by Shengmenart with modification.

Funding

This research was supported by the Shenzhen Science and Technology Innovation Commission (JCYJ20180228162311024).

Conflicts of Interest

None.

References

[1]. Committee on Obstetric. Practice Committee Opinion No. 712. Intrapartum management of intraamniotic infection. Obstet Gynecol 2017;130(2):e95–e101. doi:10.1097/AOG.0000000000002236.
[2]. Higgins RD, Saade G, Polin RA, et al. Evaluation and management of women and newborns with a maternal diagnosis of chorioamnionitis: summary of a workshop. Obstet Gynecol 2016;127(3):426–436. doi:10.1097/AOG.0000000000001246.
[3]. Ona S, Easter SR, Prabhu M, et al. Diagnostic validity of the proposed eunice kennedy shriver national institute of child health and human development criteria for intrauterine inflammation or infection. Obstet Gynecol 2019;133(1):33–39. doi:10.1097/AOG.0000000000003008.
[4]. Tita AT, Andrews WW. Diagnosis and management of clinical chorioamnionitis. Clin Perinatol 2010;37(2):339–354. doi:10.1016/j.clp.2010.02.003.
[5]. Kim CJ, Romero R, Chaemsaithong P, et al. Acute chorioamnionitis and funisitis: definition, pathologic features, and clinical significance. Am J Obstet Gynecol 2015;213(4 Suppl):S29–S52. doi:10.1016/j.ajog.2015.08.040.
[6]. Oh KJ, Kim SM, Hong JS, et al. Twenty-four percent of patients with clinical chorioamnionitis in preterm gestations have no evidence of either culture-proven intraamniotic infection or intraamniotic inflammation. Am J Obstet Gynecol 2017;216(6):604e1–604e11. doi:10.1016/j.ajog.2017.02.035.
[7]. Johnson CT, Farzin A, Burd I. Current management and long-term outcomes following chorioamnionitis. Obstet Gynecol Clin North Am 2014;41(4):649–669. doi:10.1016/j.ogc.2014.08.007.
[8]. Hadley EE, Discacciati A, Costantine MM, et al. Maternal is associated with chorioamnionitis and earlier indicated preterm delivery among expectantly managed women with preterm premature rupture of membranes. J Matern Fetal Neonatal Med 2019;32(2):271–278. doi:10.1080/14767058.2017.1378329.
[9]. Zhang Y, Yu Y, Chen L, et al. Risk factors of intra-amniotic infection related to induction with single-balloon catheter: a case-control study. Gynecol Obstet Invest 2019;84(2):183–189. doi:10.1159/000493795.
[10]. Oh KJ, Romero R, Park JY, et al. Evidence that antibiotic administration is effective in the treatment of a subset of patients with intra-amniotic infection/inflammation presenting with cervical insufficiency. Am J Obstet Gynecol 2019;221(2):140e1–140e18. doi:10.1016/j.ajog.2019.03.017.
[11]. Cobo T, Vives I, Rodríguez-Trujillo A, et al. Impact of microbial invasion of amniotic cavity and the type of microorganisms on short-term neonatal outcome in women with preterm labor and intact membranes. Acta Obstet Gynecol Scand 2017;96(5):570–579. doi:10.1111/aogs.13095.
[12]. Chaemsaithong P, Romero R, Docheva N, et al. Comparison of rapid MMP-8 and interleukin-6 point-of-care tests to identify intra-amniotic inflammation/infection and impending preterm delivery in patients with preterm labor and intact membranes. J Matern Fetal Neonatal Med 2018;31(2):228–244. doi:10.1080/14767058.2017.1281904.
[13]. DiGiulio DB, Romero R, Amogan HP, et al. Microbial prevalence, diversity and abundance in amniotic fluid during preterm labor: a molecular and culture-based investigation. PLoS One 2008;3(8):e3056. doi:10.1371/journal.pone.0003056.
[14]. Gomez-Lopez N, Romero R, Leng Y, et al. The origin of amniotic fluid monocytes/macrophages in women with intra-amniotic inflammation or infection. J Perinat Med 2019;47(8):822–840. doi:10.1515/jpm-2019-0262.
[15]. Gomez R, Romero R, Ghezzi F, et al. The fetal inflammatory response syndrome. Am J Obstet Gynecol 1998;179(1):194–202. doi:10.1016/s0002-9378(98)70272-8.
[16]. Lee J, Romero R, Kim SM, et al. A new antibiotic regimen treats and prevents intra-amniotic inflammation/infection in patients with preterm PROM. J Matern Fetal Neonatal Med 2016;29(17):2727–2737. doi:10.3109/14767058.2015.1103729.
[17]. Myntti T, Rahkonen L, Pätäri-Sampo A, et al. Comparison of amniotic fluid matrix metalloproteinase-8 and cathelicidin in the diagnosis of intra-amniotic infection. J Perinatol 2016;36(12):1049–1054. doi:10.1038/jp.2016.147.
[18]. Odibo AO, Rodis JF, Sanders MM, et al. Relationship of amniotic fluid markers of intra-amniotic infection with histopathology in cases of preterm labor with intact membranes. J Perinatol 1999;19(6 Pt 1):407–412. doi:10.1038/sj.jp.7200210.
[19]. Rodríguez-Trujillo A, Cobo T, Vives I, et al. Gestational age is more important for short-term neonatal outcome than microbial invasion of the amniotic cavity or intra-amniotic inflammation in preterm prelabor rupture of membranes. Acta Obstet Gynecol Scand 2016;95(8):926–933. doi:10.1111/aogs.12905.
[20]. Romero R, Miranda J, Kusanovic JP, et al. Clinical chorioamnionitis at term I: microbiology of the amniotic cavity using cultivation and molecular techniques. J Perinat Med 2015;43(1):19–36. doi:10.1515/jpm-2014-0249.
[21]. Romero R, Chaemsaithong P, Docheva N, et al. Clinical chorioamnionitis at term VI: acute chorioamnionitis and funisitis according to the presence or absence of microorganisms and inflammation in the amniotic cavity. J Perinat Med 2016;44(1):33–51. doi:10.1515/jpm-2015-0119.
[22]. Yoneda N, Yoneda S, Niimi H, et al. Polymicrobial amniotic fluid infection with mycoplasma/ureaplasma and other bacteria induces severe intra-amniotic inflammation associated with poor perinatal prognosis in preterm labor. Am J Reprod Immunol 2016;75(2):112–125. doi:10.1111/aji.12456.
[23]. Yoneda N, Yoneda S, Niimi H, et al. Sludge reflects intra-amniotic inflammation with or without microorganisms. Am J Reprod Immunol 2018;79(2):e12807–e12814. doi:10.1111/aji.12807.
[24]. Kusanovic JP, Vargas P, Ferrer F, et al. Comparison of two identification and susceptibility test kits for Ureaplasma spp and Mycoplasma hominis in amniotic fluid of patients at high risk for intra-amniotic infection. J Matern Fetal Neonatal Med 2019;1–9. doi:10.1080/14767058.2019.1572742.
    [25]. Filipello V, Amato E, Gori M, et al. Epidemiology and molecular typing of pregnancy-associated Listeriosis cases in lombardy, Italy, over a 10-year period (2005-2014). Infect Dis Obstet Gynecol 2017;2017:6479121. doi:10.1155/2017/6479121.
      [26]. Lu B, Wu J, Yang J, et al. Listeriosis in two twin pregnancies after in vitro fertilization with differential outcome and literature review. J Matern Fetal Neonatal Med 2019;32(10):1741–1746. doi:10.1080/14767058.2017.1410790.
        [27]. Kusanovic JP, Romero R, Martinovic C, et al. Transabdominal collection of amniotic fluid “sludge” and identification of Candida albicans intra-amniotic infection. J Matern Fetal Neonatal Med 2018;31(10):1279–1284. doi:10.1080/14767058.2017.1315095.
          [28]. Barth T, Broscheit J, Bussen S, et al. Maternal sepsis and intrauterine fetal death resulting from Candida tropicalis chorioamnionitis in a woman with a retained intrauterine contraceptive device. Acta Obstet Gynecol Scand 2002;81(10):981–982. doi:10.1034/j.1600-0412.2002.811014.x.
            [29]. Qureshi F, Jacques SM, Bendon EW, et al. Candida funisitis: a clinicopathologic study of 32 cases. Pediatr Dev Pathol 1998;1(2):118–124. doi:10.1007/s100249900014.
              [30]. Taweevisit M, Nisagornsen C, Thorner PS. Intrauterine tuberculosis manifesting as acute chorioamnionitis: a case report and review of the literature. Pediatr Dev Pathol 2015;18(4):335–338. doi:10.2350/15-02-1607-CR.1.
                [31]. Garcia-Flores J, Cruceyra M, Cañamares M, et al. Candida chorioamnionitis: report of two cases and review of literature. J Obstet Gynaecol 2016;36(7):843–844. doi:10.1080/01443615.2016.1196479.
                  [32]. Ganer Herman H, Mevorach Zussman N, Krajden Haratz K, et al. Candida glabrata chorioamnionitis following in vitro fertilization: review of the literature. Gynecol Obstet Invest 2015;80(3):145–147. doi:10.1159/000431221.
                    [33]. Kikhney J, von Schöning D, Steding I, et al. Is Ureaplasma spp. the leading causative agent of acute chorioamnionitis in women with preterm birth? Clin Microbiol Infect 2017;23(2):119e1–119e7. doi:10.1016/j.cmi.2016.10.010.
                      [34]. Silwedel C, Speer CP, Glaser K. Ureaplasma-associated prenatal, perinatal, and neonatal morbidities. Expert Rev Clin Immunol 2017;13(11):1073–1087. doi:10.1080/1744666X.2017.1381559.
                        [35]. Tantengco OAG, Yanagihara I. Current understanding and treatment of intra-amniotic infection with Ureaplasma spp. J Obstet Gynaecol Res 2019;45(9):1796–1808. doi:10.1111/jog.14052.
                          [36]. Oh KJ, Lee KA, Sohn YK, et al. Intraamniotic infection with genital mycoplasmas exhibits a more intense inflammatoryresponse than intraamniotic infection with other microorganisms in patients with preterm premature rupture of membranes. Am J Obstet Gynecol 2010;203(3):211e1–211e8. doi:10.1016/j.ajog.2010.03.035.
                            [37]. Yoon BH, Romero R, Park JS, et al. Microbial invasion of the amniotic cavity with Ureaplasma urealyticum is associated with a robust host response in fetal, amniotic, and maternal compartments. Am J Obstet Gynecol 1998;179(5):1254–1260. doi:10.1016/s0002-9378(98)70142-5.
                              [38]. Madjunkov M, Chaudhry S, Ito S. Listeriosis during pregnancy. Arch Gynecol Obstet 2017;296(2):143–152. doi:10.1007/s00404-017-4401-1.
                              [39]. Mylonakis E, Paliou M, Hohmann EL, et al. Listeriosis during pregnancy: a case series and review of 222 cases. Medicine (Baltimore) 2002;81(4):260–269. doi:10.1097/00005792-200207000-00002.
                              [40]. Gotsch F, Romero R, Kusanovic JP, et al. The fetal inflammatory response syndrome. Clin Obstet Gynecol 2007;50(3):652–683. doi:10.1097/GRF.0b013e31811ebef6.
                              [41]. Helmo FR, Alves EAR, Moreira RAA, et al. Intrauterine infection, immune system and premature birth. J Matern Fetal Neonatal Med 2018;31(9):1227–1233. doi:10.1080/14767058.2017.1311318.
                              [42]. Tann CJ, Nakakeeto M, Willey BA, et al. Perinatal risk factors for neonatal encephalopathy: an unmatched case-control study. Arch Dis Child Fetal Neonatal Ed 2018;103(3):F250–F256. doi:10.1136/archdischild-2017-312744.
                              [43]. Zackler A, Flood P, Dajao R, et al. Suspected chorioamnionitis and myometrial contractility: mechanisms for increased risk of cesarean delivery and postpartum hemorrhage. Reprod Sci 2019;26(2):178–183. doi:10.1177/1933719118778819.
                              [44]. Freud A, Wainstock T, Sheiner E, et al. Maternal chorioamnionitis and long term neurological morbidity in the offspring. Eur J Paediatr Neurol 2019;23(3):484–490. doi:10.1016/j.ejpn.2019.03.005.
                              [45]. Brown R, Gagnon R, Delisle MF. No. 373-cervical insufficiency and cervical cerclage. J Obstet Gynaecol Can 2019;41(2):233–247. doi:10.1016/j.jogc.2018.08.009.
                              [46]. Mönckeberg M, Valdés R, Kusanovic JP, et al. Patients with acute cervical insufficiency without intra-amniotic infection/inflammation treated with cerclage have a good prognosis. J Perinat Med 2019;47(5):500–509. doi:10.1515/jpm-2018-0388.
                              [47]. Palmsten K, Nelson KK, Laurent LC, et al. Subclinical and clinical chorioamnionitis, fetal vasculitis, and risk for preterm birth: a cohort study. Placenta 2018;67:54–60. doi:10.1016/j.placenta.2018.06.001.
                              [48]. Villamor-Martinez E, Cavallaro G, Raffaeli G, et al. Chorioamnionitis as a risk factor for retinopathy of prematurity: an updated systematic review and meta-analysis. PLoS One 2018;13(10):e0205838. doi:10.1371/journal.pone.0205838.
                              [49]. Venkatesh KK, Glover AV, Vladutiu CJ, et al. Association of chorioamnionitis and its duration with adverse maternal outcomes by mode of delivery: a cohort study. BJOG 2019;126(6):719–727. doi:10.1111/1471-0528.15565.
                              [50]. Xiao D, Zhu T, Qu Y, et al. Maternal chorioamnionitis and neurodevelopmental outcomes in preterm and very pretermneonates: a meta-analysis. PLoS One 2018;13(12):e0208302. doi:10.1371/journal.pone.0208302.
                              [51]. Paules C, Moreno E, Gonzales A, et al. Amniotic fluid sludge as a marker of intra-amniotic infection and histologicalchorioamnionitis in cervical insufficiency: a report of four cases and literature review. J Matern Fetal Neonatal Med 2016;29(16):2681–2684. doi:10.3109/14767058.2015.1101445.
                              [52]. American College of Obstetricians Gynecologists. ACOG practice bulletin no.142: cerclage for the management of cervical insufficiency. Obstet Gynecol 2014;123(2 Pt 1):372–379. doi:10.1097/01.AOG.0000443276.68274.cc.
                              [53]. Liu Y, Liu Y, Zhang R, et al. Early- or mid-trimester amniocentesis biomarkers for predicting preterm delivery: a meta-analysis. Ann Med 2017;49(1):1–10. doi:10.1080/07853890.2016.1211789.
                              [54]. Cataño Sabogal CP, Fonseca J, García-Perdomo HA. Validation of diagnostic tests for histologic chorioamnionitis: systematic review and meta-analysis. Eur J Obstet Gynecol Reprod Biol 2018;228:13–26. doi:10.1016/j.ejogrb.2018.05.043.
                              [55]. Kurakazu M, Yotsumoto F, Arima H, et al. The combination of maternal blood and amniotic fluid biomarkers improves the predictiveaccuracy of histologic chorioamnionitis. Placenta 2019;80:4–7. doi:10.1016/j.placenta.2019.03.007.
                              [56]. Dulay AT, Buhimschi IA, Zhao G, et al. Compartmentalization of acute phase reactants Interleukin-6, C-reactive protein and procalcitonin as biomarkers of intra-amniotic infection and chorioamnionitis. Cytokine 2015;76(2):236–243. doi:10.1016/j.cyto.2015.04.014.
                              [57]. Redline RW, Faye-Petersen O, Heller D, et al. Amniotic infection syndrome: nosology and reproducibility of placental reaction patterns. Pediatr Dev Pathol 2003;6(5):435–448. doi:10.1007/s10024-003-7070-y.
                              [58]. Redline RW. Classification of placental lesions. Am J Obstet Gynecol 2015;213(4 Suppl):S21–S28. doi:10.1016/j.ajog.2015.05.056.
                              [59]. American Association of Pro-Life Obstetricians Gynecologists. AAPLOG practice bulletin no. 3: previable induction of labor for chorioamnitis. Issues Law Med 2018;33(2):247–256.
                              [60]. Schmitz T, Sentilhes L, Lorthe E, et al. Preterm premature rupture of the membranes: guidelines for clinical practice from the French College of Gynaecologists and Obstetricians (CNGOF). Eur J Obstet Gynecol Reprod Biol 2019;236:1–6. doi:10.1016/j.ejogrb.2019.02.021.
                              [61]. Lim SL, Havrilesky LJ, Heine RP, et al. The cost-effectiveness of ertapenem for the treatment of chorioamnionitis after cesarean delivery. J Matern Fetal Neonatal Med 2019;1–6. doi: 10.1080/14767058.2019.1597042.
                                [62]. Tanaka S, Tsumura K, Nakura Y, et al. New antibiotic regimen for preterm premature rupture of membrane reduces the incidence of bronchopulmonary dysplasia. J Obstet Gynaecol Res 2019;45(5):967–973. doi:10.1111/jog.13903.
                                  [63]. Dotters-Katz SK, Feldman C, Puechl A, et al. Risk factors for post-operative wound infection in the setting of chorioamnionitis and cesarean delivery. J Matern Fetal Neonatal Med 2016;29(10):1541–1545. doi:10.3109/14767058.2015.1058773.
                                    [64]. Yoon BH, Romero R, Park JY, et al. Antibiotic administration can eradicate intra-amniotic infection or intra-amniotic inflammation in a subset of patients with preterm labor and intact membranes. Am J Obstet Gynecol 2019;221(2):142e1–142e22. doi:10.1016/j.ajog.2019.03.018.
                                    [65]. Pustotina O. Effects of antibiotic therapy in women with the amniotic fluid “sludge" at 15-24 weeks of gestation on pregnancy outcomes. J Matern Fetal Neonatal Med 2019;27:1–12. doi:10.1080/14767058.2019.1567706.
                                    [66]. Locksmith GJ, Chin A, Vu T, et al. High compared with standard gentamicin dosing for chorioamnionitis: a comparison of maternal and fetal serum drug levels. Obstet Gynecol 2005;105(3):473–479. doi:10.1097/01.AOG.0000151106.87930.1a.
                                    [67]. Kirkwood A, Harris C, Timar N, et al. Is gentamicin ototoxic to the fetus? J Obstet Gynaecol Can 2007;29(2):140–145. doi:10.1016/s1701-2163(16)32381-7.
                                    [68]. Martingano D, Renson A, Rogoff S, et al. Daily gentamicin using ideal body weight demonstrates lower risk of postpartum endometritis and increased chance of successful outcome compared with traditional 8-hour dosing for the treatment of intrapartum chorioamnionitis. J Matern Fetal Neonatal Med 2019;32(19):3204–3208. doi:10.1080/14767058.2018.1460348.
                                    [69]. Horinouchi T, Yoshizato T, Kozuma Y, et al. Prediction of histological chorioamnionitis and neonatal and infantile outcomes using procalcitonin in the umbilical cord blood and amniotic fluid at birth. J Obstet Gynaecol Res 2018;44(4):630–636. doi:10.1111/jog.13573.
                                    [70]. Frerot A, Baud O, Colella M, et al. Cord blood procalcitonin level and early-onset sepsis in extremely preterm infants. Eur J Clin Microbiol Infect Dis 2019;38(9):1651–1657. doi:10.1007/s10096-019-03593-0.
                                    [71]. Hastings-Tolsma M, Bernard R, Brody MG, et al. Chorioamnionitis: prevention and management. MCN Am J Matern Child Nurs 2013;38(4):206–212. doi:10.1097/NMC.0b013e3182836bb7.
                                    Keywords:

                                    Chorioamnionitis; Intraamniotic infection; Maternal infection; Fetal infection; Cervical insufficiency; Organisms

                                    Copyright © 2020 The Chinese Medical Association, published by Wolters Kluwer Health, Inc.